Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Quest Pharmatech Inc V.QPT

Alternate Symbol(s):  QPTFF

Healthcare Biotechnology
Quest PharmaTech Inc. is a Canadian biopharmaceutical company. The Company is developing products to improve the quality of life. It is developing the proprietary, MAb-AR9.6, targeting MUC16 as a diagnostic agent for cancer. MAb-AR9.6 is licensed from the University of Nebraska Medical Centre and is in late preclinical stage development. The Company has a 42.5% ownership interest in OncoQuest Inc., which is a biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest Inc.’s technology platform includes a panel of tumor antigen specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent, which is developing antibody-based immunotherapeutic products for cancer in the Greater China territory.


TSXV:QPT - Post by User

Quest Pharmatech Inc > Hmm...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(97)
•••
Comment by G1945Von Jul 22, 2022 8:29am
164 Views
Post# 34842547

RE:RE:Hmm...

RE:RE:Hmm...
G1945V wrote:
ARIMA11 wrote: https://ceo.ca/qpt?628915064c02  
https://pulsenews.co.kr/view.php?sc=30800028&year=2022&no=360177

Canariabio is issuing convertible bonds worth 70 billion won to finance the deal, along with 20 billion won pooled from its affiliated entities.

As pointed out by Zippo on CEO.ca, Canaribio continues to acquire companies. This time in the feed business. The way they make that acquisition is also through a convertable bonds. 90B this time.

In comparison the QPT deal is small potatoes but reading this is not comforting. 


Thanks ARIMA11,  for the explanation.

I did email Pierre Vermette. Have not heard back as yet. 

G1945V

I cannot believe that all of this new information as you are pointing out is not material news for the shareholders of Quest Pharmatech Inc. (QPT)  Dr. Madi Madiyalakan being the CEO of both Quest Pharmatech (QPT) and  OncoQuest Inc. should without further delay put out a news release outlining in detail all he expressed at the AGM telephone conference on July 19, 2022, as to what has changed from the original agreement as announced on April 22, 2020  (https://stockhouse.com/news/press-releases/2020/04/22/oncoquest-signs-a-definitive-agreement-to-sell-drug-portfolio-to-dual) and what followed as apposed to getting this information in bits and pieces from other sources.  

JMO
G1945V

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities